Pharmaceuticals

Rising incidence of chronic kidney disease fueling treatment demand is a key growth driver for the Biopoin Market 2026

March 25, 2026March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Biopoin Market During The Forecast Period 2026–2030?

Historically, expansion was largely fueled by the documented clinical efficacy of epoetin treatments, a simultaneous increase in the dialysis patient demographic, the growing prevalence of anemia associated with chemotherapy, the establishment of hospital-centric anemia management guidelines, and advancements in hemoglobin level surveillance.

The projected growth in the upcoming period is driven by an increase in chronic renal failure cases, the expansion of supportive care in oncology, greater access to biosimilar epoetins, evolving aging population demographics, and a heightened focus on managing fatigue associated with anemia. Significant trends during this forecast period include the increasing adoption of erythropoiesis stimulating agents, a rising burden of anemia among individuals with chronic kidney disease, continued expansion of supportive oncology care, a shift towards longer-acting therapies for managing anemia, and an enhanced emphasis on improving the quality of life for patients experiencing chronic anemia.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20002&type=smp

Which Major Factors Are Driving The Expansion Of The Biopoin Market?

The rising occurrence of chronic kidney disease (CKD) is anticipated to fuel the expansion of the biopoin market in the coming years. CKD is a persistent ailment marked by a progressive decline in kidney function, hindering the kidneys’ capacity to efficiently remove waste and excess fluids from the blood. The increased incidence of chronic kidney disease primarily stems from escalating rates of diabetes, hypertension, and poor dietary habits. In individuals with CKD, diminished erythropoietin production results in anemia, leading to fatigue and weakness. Biopoin, which contains epoetin theta, promotes the generation of red blood cells, thereby elevating hemoglobin levels and enhancing the overall quality of life. For example, in October 2024, the National Health Service, a UK government agency, reported that the prevalence and severity of chronic kidney disease increase with age, impacting nearly half of adults aged 75 and above across stages 1 to 5 (48%), with over a third experiencing the more advanced stages 3 to 5 (36%). Additionally, in June 2023, Oxford Academic, a UK-based publishing firm, stated that from 2022 to 2032, the population affected by chronic kidney disease (CKD) in the UK is expected to increase by 4%, from 8.27 million to 8.61 million. Consequently, the increasing cases of chronic kidney disease are propelling the growth of the biopoin market. The expanding occurrence of anemia is projected to stimulate the growth of the biopoin market moving forward. Anemia refers to a state marked by an insufficient count of red blood cells or a low amount of hemoglobin in the blood, which diminishes the body’s capacity to transport oxygen to its tissues. This widespread presence of anemia is primarily a result of nutritional shortages, as inadequate consumption of iron, vitamin B12, and folate hinders red blood cell formation. BioPoin improves anemia management through precise diagnostics and monitoring, making it particularly beneficial for individuals lacking iron, vitamin B12, or folate. It facilitates prompt interventions, thereby boosting treatment effectiveness and overall health outcomes for patients. As an illustration, in April 2024, the World Health Organization, an intergovernmental organization based in Switzerland, reported that roughly 30.7% of women aged 15-49 years were affected by anaemia in 2023. Consequently, the rising prevalence of anemia is fostering the expansion of the biopoin market.

What Market Segments Are Evaluated Within The Biopoin Market?

The biopoin market covered in this report is segmented –

1) By Indication: Anemia In Chronic Kidney Disease, Cancer-Related Anemia, Surgical Anemia, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

3) By End User: Adult, Geriatric, Pediatric

Who Are The Top Market Participants Influencing The Biopoin Market?

Major companies operating in the biopoin market are Teva Pharmaceutical Industries

Read the full biopoin market report here:

https://www.thebusinessresearchcompany.com/report/biopoin-global-market-report

Which Region Currently Holds The Largest Share Of The Biopoin Market?

North America was the largest region in the biopoin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopoin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biopoin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20002&type=smp

Browse Through More Reports Similar to the Global Biopoin Market 2026, By The Business Research Company

Biocomposites Market Report 2026

https://www.thebusinessresearchcompany.com/report/biocomposites-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Biotech Ingredient Market Report 2026

https://www.thebusinessresearchcompany.com/report/biotech-ingredient-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795